4D Molecular Therapeutics, Inc. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/0daf19c0-d5ee-4b6c-b853-3abd850c0607/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-159.5M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-114075 |
| FY 2024 | $-187.8M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-030056 |
| FY 2023 | $-112.9M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-023183 |
| FY 2022 | $-110.0M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-008142 |
| FY 2021 | $-71.3M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-004794 |
| FY 2020 | $-56.7M | 2020-01-01 – 2020-12-31 | evidence 0001564590-21-015502 |
| FY 2019 | $-50.8M | 2019-01-01 – 2019-12-31 | evidence 0001564590-21-015502 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
4D Molecular Therapeutics, Inc. — all facts · Revenue · Net Income